Capricor Therapeutics to Announce Q2 2024 Financials and Corporate Update on August 7

Capricor Therapeutics, a biotechnology company listed on NASDAQ under the symbol CAPR, is renowned for its development of transformative cell and exosome-based treatments aimed at addressing rare diseases. The company is set to release its financial results for the second quarter ending June 30, 2024. This announcement will be made public after the market closes on August 7, 2024. Following the release, Capricor's management team will conduct a webcast and conference call at 4:30 p.m. ET on the same day. The call details are as follows: the toll-free number is 1-800-717-1738, the international number is 1-646-307-1865, and the conference ID is 30827. Participants have the option to either dial in using the provided numbers or click a Call me™ link for direct access. The webcast will also be accessible via a link on Capricor's website, with a replay available post-broadcast.

Capricor Therapeutics is committed to advancing its chief product candidate, deramiocel (CAP-1002). This allogeneic cardiac-derived cell therapy has shown promising results in preclinical and clinical studies, demonstrating immunomodulatory, antifibrotic, and regenerative properties. These traits make it particularly suitable for treating dystrophinopathies and heart disease. Currently, deramiocel is progressing through Phase 3 clinical trials for treating Duchenne muscular dystrophy (DMD).

In addition to deramiocel, Capricor is leveraging its proprietary StealthX™ platform to develop exosome-based therapeutics. This platform is in the preclinical phase and focuses on areas such as vaccinology, and the targeted delivery of oligonucleotides, proteins, and small molecule therapeutics. The aim is to treat and prevent various diseases, thereby expanding the potential applications of Capricor’s technological advancements.

Capricor's innovative efforts are driven by a commitment to push the boundaries of what is possible in therapeutic development. The company aims to create transformative treatments that can significantly benefit patients suffering from rare diseases. For more updates and detailed information, interested parties are encouraged to visit Capricor's website and follow their social media channels on Facebook, Instagram, and Twitter.

Capricor Therapeutics has also secured an exclusive agreement with Nippon Shinyaku Co., Ltd., through its U.S. subsidiary NS Pharma, Inc., for the commercialization and distribution of deramiocel in the United States and Japan. This partnership is contingent on regulatory approval. It is important to note that deramiocel is still an Investigational New Drug and has not received approval for any specific indications. Similarly, none of Capricor’s exosome-based candidates have been approved for clinical investigation at this time. 

The upcoming financial results announcement and subsequent conference call will likely provide further insights into Capricor's recent progress and future plans, including updates on their clinical trials and regulatory strategies. This event is of interest to shareholders, potential investors, and stakeholders in the biotechnological and pharmaceutical sectors as it will shed light on the company’s current financial health and strategic direction.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!